Adaptive Radiotherapy Simplified
ART.1 is available for clinical use in the United Kingdom, the European Union and Australia. ART.1-US is FDA cleared and available for clinical use in the US.
What our users are saying
“I’m really pleased we’ve got ART.1 which cuts down so much time, it makes everything so much easier”
– Medical Physicist (UK)
“The fact that it sits in the background and calculates
everything for you...that's the ideal workflow."
– Radiation Oncologist (Aus)
“The efficiency of the ART.1 software and personalisation of care helps us match our clinical team’s effort and valuable resource time to support the best possible outcomes for our patients”
– Radiation Oncologist (Aus)
“With ART.1 you can assess a series of fractions within a couple of minutes, we’re seeing the ability to verify more information for more patients with the same time commitment”
– Medical Physicist (Aus)
Every Structure
ART.1 analyzes every structure, allowing configurable, personalized protocols to analyze any structure with any metric.
Your department workflow, your protocols, your results.
Every Fraction
ART.1’s fraction-by-fraction deviation analysis provides a history of results, boosting confidence in replan decisions.
Your patient’s treatment story is unique.
Every Patient
ART.1 automatically evaluates all patients in the background, prioritizing those who need attention the most, allowing for adaptive decision-making in minutes.
Adaptive RT without barriers:
All-in-one solution:
Automatic robust image registration and dose calculation built in.
Agentic monitoring:
Trend plots and traffic-light alerts surface only the patients who need attention.
Universal Compatibility:
Complete automation and integration with major vendors
Evidence-based adaptive decisions:
Objective decision support, replan at your pace.
About Us
Founded by Dr Trang Nguyen and Prof Paul Keall in 2023, SeeTreat is led by award-winning researchers, engineers, and clinicians with a combined experience in radiation oncology of over 300 years.
Transforming treatment without hardware barriers
We develop software solutions that enhance patient care and clinical efficiency without requiring hardware upgrades.
People-first innovation
At the heart of SeeTreat is a passion for solving real-world problems in cancer treatment. We are committed to improving the experiences of both patients and clinicians. Our workplace culture is built on innovation, collaboration, and inclusivity, where diverse perspectives are valued, and bold ideas are encouraged.
“ART.1 changes what's possible in adaptive radiotherapy. It gives clinicians continuous visibility into how treatment is evolving for each patient, bridging the gap between planning and real-world delivery in a way that's been missing until now”
Prof. Jarad MartinPracticing radiation oncologist (MBChB BSc PhD DMed FRANZCR GAustMS)
SeeTreat News
C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic
C-RAD and SeeTreat partner to co-develop personalised radiotherapy for every patient in every clinic UPPSALA, Sweden/SYDNEY, Australia – September 29, 2026 – C-RAD (publ) the global leader in surface-guided radiation therapy (SGRT), and SeeTreat Pty Ltd, a pioneer in the adaptive decision support radiotherapy (ART) software, today confirm a partnership to co-develop more connected, intelligent, and patient-centric radiotherapy workflows.
Read more
ABC Radio National interview - Changing Australia: Paul Keall and innovating with radiotherapy
SeeTreat co-founder Professor Paul Keall speaks with Sally Sara on innovating with radiotherapy. Prof Keall writes of this interview: "It was an honour to be invited to contribute to the ABC's Changing Australia series hosted by Sally Sara. On the question of how to bring innovations in radiotherapy to large numbers of patients I am proud that we at SeeTreat are doing just that: developing accessible technology to ensure that the radiation treatment is personalised to the patient throughout their course of therapy."
Read more
SeeTreat's ART.1-US Software is FDA Cleared for clinical use in the USA
SYDNEY, May 18, 2026 /PRNewswire/ -- SeeTreat's ART.1-US software delivering automated adaptive decision support for every patient at every treatment is cleared for use in the USA. From today, US clinics with Varian or Elekta CT linear accelerators, will be able to access daily evaluations of radiotherapy dose to patients' changing anatomy. With ART.1-US, clinical teams can now decide the right time for a new radiotherapy plan in 95+ seconds[1], and download supporting clinical documentation.
Read more
GenesisCare and SeeTreat to bring personalised Offline Adaptive Monitoring to more than 40 radiation oncology centres across Australia
SYDNEY, May 14, 2026 /PRNewswire/ -- Leading Australian cancer care provider, GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable cancer patients access to the latest technology in offline adaptive treatment assessment. SeeTreat's ART.1 software will be rolled out at GenesisCare from July 2026 to support automated, adaptive treatment evaluation for eligible patients.
Read more